Downregulation of long noncoding RNA FENDRR predicts poor prognosis in renal cell carcinoma

He,Wang; Zhong,Guangzheng; Wang,Pei; Jiang,Chun; Jiang,Ning; Huang,Jian

doi:10.3892/ol.2018.9624

Downregulation of long noncoding RNA FENDRR predicts poor prognosis in renal cell carcinoma

Authors:
- Wang He
- Guangzheng Zhong
- Pei Wang
- Chun Jiang
- Ning Jiang
- Jian Huang
View Affiliations

Affiliations: Department of Urology, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510120, P.R. China, Department of Emergency Surgery, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China
Published online on: October 26, 2018 https://doi.org/10.3892/ol.2018.9624
Pages: 103-112
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long noncoding RNA FOXF1 adjacent non‑coding developmental regulatory RNA (FENDRR) dysregulation associates with multiple types of human cancer. However, the biological functions of FENDRR in renal cell carcinoma are unresolved. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to determine the expression level of FENDRR in renal cell carcinoma tissues. An RNA interference assay and ectopic expression experiments were conducted to evaluate the effects of FENDRR on cell proliferation, migration, invasion and colony formation in vitro. RNA immunoprecipitation was conducted to identify proteins associated with FENDRR. It was observed that FENDRR is frequently downregulated in renal cell carcinoma and overexpression of FENDRR attenuated proliferation, migration, invasion and colony growth of renal carcinoma cells. Conversely, knockdown of FENDRR promotes proliferation and invasiveness of renal carcinoma cells. Downregulation of FENDRR associates with poor prognosis of renal cell carcinoma. Mechanistically, it was identified that FENDRR may bind to Polycomb Repressive Complex 2 and lysin methyltransferase 2A histone modifying complexes. In summary, FENDRR acts as an tumor suppressor in renal cell carcinoma and may serve as a candidate target for gene therapy.

View Figures

View References

1	Jonasch E, Gao J and Rathmell WK: Renal cell carcinoma. BMJ. 349:g47972014. View Article : Google Scholar : PubMed/NCBI
2	Hollingsworth JM, Miller DC, Daignault S and Hollenbeck BK: Five-year survival after surgical treatment for kidney cancer: A population-based competing risk analysis. Cancer. 109:1763–1768. 2007. View Article : Google Scholar : PubMed/NCBI
3	Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
4	Mourad WF, Dutcher J and Ennis RD: State-of-the-art management of renal cell carcinoma. Am J Clin Oncol. 37:498–505. 2014. View Article : Google Scholar : PubMed/NCBI
5	Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 27:3312–3318. 2009. View Article : Google Scholar : PubMed/NCBI
6	Grote P, Wittler L, Hendrix D, Koch F, Währisch S, Beisaw A, Macura K, Bläss G, Kellis M, Werber M and Herrmann BG: The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell. 24:206–214. 2013. View Article : Google Scholar : PubMed/NCBI
7	Xu TP, Huang MD, Xia R, Liu XX, Sun M, Yin L, Chen WM, Han L, Zhang EB, Kong R, De W, et al: Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. J Hematol Oncol. 7:632014. View Article : Google Scholar : PubMed/NCBI
8	Chen R, Li WX, Sun Y, Duan Y, Li Q, Zhang AX, Hu JL, Wang YM and Gao YD: Comprehensive analysis of lncRNA and mRNA expression profiles in lung cancer. Clin Lab. 63:313–320. 2017. View Article : Google Scholar : PubMed/NCBI
9	Sauvageau M, Goff LA, Lodato S, Bonev B, Groff AF, Gerhardinger C, Sanchez-Gomez DB, Hacisuleyman E, Li E, Spence M, et al: Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife. 2:e017492013. View Article : Google Scholar : PubMed/NCBI
10	Grote P and Herrmann BG: The long non-coding RNA Fendrr links epigenetic control mechanisms to gene regulatory networks in mammalian embryogenesis. RNA Biol. 10:1579–1585. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang H and Men CP: Correlation of increased expression of MicroRNA-155 in bladder cancer and prognosis. Lab Med. 46:118–122. 2015. View Article : Google Scholar : PubMed/NCBI
12	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	He W, Cai Q, Sun F, Zhong G, Wang P, Liu H, Luo J, Yu H, Huang J and Lin T: linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer. Biochim Biophy Acta. 1832:1528–1537. 2013. View Article : Google Scholar
15	Li Q, Wu C, Song G, Zhang H, Shan B, Duan Y and Wang Y: Genome-wide analysis of long noncoding RNA expression profiles in human Xuanwei lung cancer. Clin Lab. 61:1515–1523. 2015. View Article : Google Scholar : PubMed/NCBI
16	Vieira-Coimbra M, Henrique R and Jeronimo C: New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours. Eur J Clin Invest 45 (Suppl). 1:S16–S24. 2015. View Article : Google Scholar
17	Schuettengruber B, Chourrout D, Vervoort M, Leblanc B and Cavalli G: Genome regulation by polycomb and trithorax proteins. Cell. 128:735–745. 2007. View Article : Google Scholar : PubMed/NCBI
18	Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, et al: Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genetics. 39:232–236. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Chen Y, Geng H, Qi C, Liu Y and Yue D: Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas. Tumour Biol. 36:7159–7166. 2015. View Article : Google Scholar : PubMed/NCBI
20	Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
21	Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, et al: Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 106:11667–11672. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J and Guo J: EZH2 promotes tumor cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 117:351–362. 2016. View Article : Google Scholar : PubMed/NCBI
23	Xu ZQ, Zhang L, Gao BS, Wan YG, Zhang XH, Chen B, Wang YT, Sun N and Fu YW: EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma. Clin Transl Oncol. 17:41–49. 2015. View Article : Google Scholar : PubMed/NCBI
24	Schmitz SU, Grote P and Herrmann BG: Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 73:2491–2509. 2016. View Article : Google Scholar : PubMed/NCBI
25	Chen Z, He A, Wang D, Liu Y and Huang W: Long noncoding RNA HOTTIP as a novel predictor of lymph node metastasis and survival in human cancer: A systematic review and meta-analysis. Oncotarget. 8:14126–14132. 2017.PubMed/NCBI
26	Jing W, Zhu M, Zhang XW, Pan ZY, Gao SS, Zhou H, Qiu SL, Liang CZ and Tu JC: The significance of long noncoding RNA H19 in lredicting progression and metastasis of cancers: A Meta-Analysis. Biomed Res Int. 2016:59026782016. View Article : Google Scholar : PubMed/NCBI